论文部分内容阅读
目的：探讨二甲双胍结合瑞舒伐他汀联合用药治疗初诊肥胖型2型糖尿病患者高敏C反应蛋白（ hs-CRP）水平的影响。方法将2011年6月至2013年7月于河北省保定市第四医院就诊的212例初诊肥胖型2型糖尿病患者依据随机数字表法按就诊顺序分治疗组（ n ＝106，二甲双胍联合瑞舒伐他汀治疗）和对照组（ n＝106，单纯应用二甲双胍治疗）。疗程12周。治疗结束后，检测两组患者治疗前后体质量指数、血糖、血脂、HOMA-IR指数和 hs-CRP。结果治疗后，两组患者的空腹血糖、餐后血糖、糖化血红蛋白、三酰甘油、总胆固醇、低密度脂蛋白、hs-CRP、体质量指数、HOMA-IR均低于治疗前，且治疗组低于对照组，差异有统计学意义（ P＜0．01）。结论初诊肥胖型2型糖尿病患者采用二甲双胍联合瑞舒伐他汀疗法疗效理想，在控制血糖的基础上，能够有效降低患者的血脂和hs-CRP水平，改善胰岛素抵抗，对预防糖尿病大血管并发症有积极作用。“,”Objective To investigate the combination of rosuvastatin metformin combination therapy af-fect the level of newly diagnosed type 2 diabetes in obese patients with high-sensitivity C-reactive protein ( hs-CRP) ( read) .Methods June 2011 to July 2013 in Baoding, Hebei Province, the fourth hospital 212 patients with newly diagnosed obese patients with type 2 diabetes treatment order stochastic ( random in what way?) Divided into treatment group (n=106, metformin rosuvastatin therapy) and control group (n=106, the simple application of metformin).The course of treatment was 12 weeks.Blood glucose, blood lipid, BMI HOMA-IR index, hs-CRP level were detected before and after treatment.Results After treatment, fasting blood glucose, blood glucose after meal of two groups of patients, glycosylated hemoglobin, triglycer-ide, total cholesterol, three low density lipoprotein, hs-CRP, body mass index, HOMA-IR were lower than that before treatment, and the treatment group than in the control group, the difference was statistically sig-nificant (P<0.01).Conclusion Combined therapy seems efficiency in patients with newly diagnosed o-besity type 2 diabetes, it reduced the level of serum lipid levels and level of hs-CRP on the base of blood glu-cose controlling, improved insulin resistance, and had a positive effect on prevention of diabetic vascular complication.